MoonLake Immunotherapeutics (NASDAQ: MLTX) fell in pre-market trading on Monday at the time of publishing after a Reuters report that the developer of antibodies used in the treatment of inflammatory skin conditions is exploring a sale.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The report stated that the company is in early-stage discussions with drugmakers interested in acquiring the company. According to Reuters, no deal is certain and the discussions are still confidential.
MLTX stock has soared by more than 300% year-to-date.